Background: Dupuytren disease creates thickened cords of the palmar fascia, leading to progressive flexion contractures that severely hinder hand function. Collagenase clostridium histolyticum (CCH) injection is a common, minimally invasive alternative to surgical excision of these cords. The impact of CCH injection on the histological architecture of Dupuytren cords has not been studied extensively. Methods: A series of 10 CCH-injected cords were evaluated histologically. Cellularity, architecture, and connective tissue organization were compared against uninjected Dupuytren cords and normal palmar fascia. Results: No significant histopathological differences between CCH-injected and CCH-uninjected cords were identified. Conclusions: Dupuytren cords do not demonstrate histological changes with prior exposure to CCH.
DibenedettiDBNguyenDZografosL, et al. Prevalence, incidence, and treatments of Dupuytren’s disease in the United States: results from a population-based study. Hand (N Y). 2011;6(2):149-158. doi:10.1007/s11552-010-9306-4.
2.
HindochaSMcGroutherDABayatA.Epidemiological evaluation of Dupuytren’s disease incidence and prevalence rates in relation to etiology. Hand (N Y). 2009;4(3):256-269. doi:10.1007/s11552-008-9160-9.
3.
RayanGM.Dupuytren disease: anatomy, pathology, presentation, and treatment. J Bone Joint Surg Am. 2007;89(1):189-198. doi:10.2106/00004623-200701000-00026.
4.
GilpinDColemanSHallS, et al. Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg Am. 2010;35(12):2027-2038.e1. doi:10.1016/j.jhsa.2010.08.007.
5.
NaamNH.Functional outcome of collagenase injections compared with fasciectomy in treatment of Dupuytren’s contracture. Hand (N Y). 2013;8(4):410-416. doi:10.1007/s11552-013-9540-7.
6.
PeimerCABlazarPColemanS, et al. Dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (CORDLESS study): 3-year data. J Hand Surg Am. 2013;38(1):12-22. doi:10.1016/j.jhsa.2012.09.028.
7.
HurstLCBadalamenteMAHentzVR, et al. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med. 2009;361(10):968-979. doi:10.1056/NEJMoa0810866.
8.
WarwickDArandes-RenúJMPajardiG, et al. Collagenase Clostridium histolyticum: emerging practice patterns and treatment advances. J Plast Surg Hand Surg. 2016;50(5):251-261. doi:10.3109/2000656X.2016.1159568.
9.
PeimerCAWilbrandSGerberRA, et al. Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren’s contracture. J Hand Surg Eur Vol. 2015;40(2):141-149. doi:10.1177/1753193414528843.
10.
SoodATherattilPJPaikAM, et al. Treatment of Dupuytren disease with injectable collagenase in a veteran population: a case series at the department of veterans affairs new jersey health care system. Eplasty. 2014;14:e13.
11.
MuppavarapuRCWatersMJLeibmanMI, et al. Clinical outcomes following collagenase injections compared to fasciectomy in the treatment of Dupuytren’s contracture. Hand (N Y). 2015;10(2):260-265. doi:10.1007/s11552-014-9704-0.
12.
ZhangDEarpBEBenaventKA, et al. Collagenase treatment of Dupuytren’s disease with minimum 5-year follow-up: recurrence, reintervention, and satisfaction. Plast Reconstr Surg. 2020;146(5):1071-1079. doi:10.1097/PRS.0000000000007243.
13.
Alfonso-RodríguezCAGarzónIGarrido-GómezJ, et al. Identification of histological patterns in clinically affected and unaffected palm regions in Dupuytren’s disease. PLoS One. 2014;9(11):e112457. doi:10.1371/journal.pone.0112457.
14.
Sanjuan-CerveroRCarrera-HuesoFJVaquero-PerezM, et al. Recurrent Dupuytren’s disease after fasciectomy and collagenase injection are histologically indistinguishable. J Hand Surg Eur Vol. 2020;45(5):508-512. doi:10.1177/1753193419900483.
